The bolus thrombolytic, tenecteplase, given at a dose of 0.25 mg/kg, was noninferior to the standard of care, alteplase, in a large, randomized trial. The 1600-patient Canadian Alteplase Compared to Tenecteplase...

Scientists recently studied the impact poor sleep can have on the eyes in a trial using mice. They learned that sleep deprivation can cause the cornea to lose its ability to repair itself properly,...

(Reuters) – Among people who were previously infected with the coronavirus, a third dose of an mRNA vaccine from Pfizer/BioNTech or Moderna may not boost their protection against the Omicron variant...

Older people with mobility problems living without home adaptations have poorer health and higher levels of pain, according to researchers at The Universities of Manchester and Hong Kong. The study of...

Seven physicians were among 12 medical professionals charged today by the US Department of Justice (DOJ) with opioid distribution offenses. In coordination with federal and state law enforcement, the...

The COVID-19 pandemic killed 13.3 to 16.6 million people in 2020 and 2021, the WHO estimated Thursday—up to triple the number of deaths attributed directly to the disease. The World Health Organization’s...

Prescriptions for multiple drugs, or polypharmacy, is often recommended for the treatment of complex diseases. However, upon ingestion, multiple drugs may interact in an undesirable manner, resulting...

Researchers at the University of York have expanded a unique regional cancer database, which will help clinicians understand more about conditions such as leukemia, lymphoma and myeloma. The expanded...

Saying becoming a new mum is a tricky experience is a massive understatement. It’s a life-changer. You’re struck with this new, giant responsibility, and have to attempt to juggle this while navigating...

The rate of hypersensitivity reactions (HSRs) to gadolinium-based contrast agents (GBCAs) is 0.4 percent, and premedication can reduce the risk for HSRs in patients with a history of acute or delayed...